Research programme: biphosphonate-vitamin B6 conjugates - MBC PharmaAlternative Names: MBC-31; MBC-4
Latest Information Update: 16 Jul 2016
At a glance
- Originator MBC Pharma
- Mechanism of Action Bone resorption factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone disorders; Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-disorders in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 30 Aug 2007 Preclinical trials in Osteoporosis in USA (PO)